Drug Information

Drug (ID: DG00915) and It's Reported Resistant Information

• Name: Nicorandil
• Synonyms: NICORANDIL; 65141-46-0; Ikorel; 2-Nicotinamidoethyl nitrate; SG-75; Dancor; Sigmart; Nicorandilum; Adancor; 2-(nicotinamido)ethyl nitrate; 2-(pyridine-3-carbonylamino)ethyl nitrate; SG 75; N-(2-Hydroxyethyl)nicotinamide nitrate; N-(2-Hydroxyethyl)nicotinamide nitrate (ester); Nicorandil (Ikorel); UNII-260456HAM0; CHEBI:31905; N-[2-(NITROOXY)ETHYL]-3-PYRIDINECARBOXAMIDE; 3-PYRIDINECARBOXAMIDE, N-[2-(NITROOXY)ETHYL]-; MFCD00186520; 260456HAM0; NCGC00025357-01; 2-(PYRIDIN-3-YLFORMAMIDO)ETHYL NITRATE; 3-Pyridinecarboxamide, N-(2-(nitrooxy)ethyl)-; DSSTox_CID_25692; DSSTox_RID_81064; DSSTox_GSID_45692; Nicorandilum [INN-Latin]; 2-[(PYRIDIN-3-YLCARBONYL)AMINO]ETHYL NITRATE; 2-(Nicotinamido)ethyl nitrat; SMR000466365; Sigmart (TN); CAS-65141-46-0; PERISALOL; n-(2-(nitrooxy)ethyl)-3-pyridinecarboxamide; SR-01000597534; EINECS 265-514-1; BRN 0481451; Nicorandilo; 3-Pyridinecarboxamide, N-(2-(nitroxy)ethyl)-; Nicorandil [USAN:INN:BAN:JAN]; Nicorandil- Bio-X; 2-(Pyridine-3-carboxamido)ethyl Nitrate; CPD000466365; RP-46417; n-(2-hydroxyethyl)nicotinamide nitrate ester; N-[2-(Nitrooxy)ethyl]pyridine-3-carboxamide; SCHEMBL34547; MLS000759488; MLS001424162; MLS002222323; MLS006010701; CHEMBL284906; GTPL2411; DTXSID8045692; Nicorandil (JP17/USAN/INN); HMS2051N16; HMS2089L12; HMS2095E14; HMS2232A06; HMS3268L19; HMS3371N18; HMS3393N16; HMS3413G17; HMS3655P05; HMS3677G17; HMS3712E14; BCP09434; HY-B0341; ZINC1533102; Tox21_110968; BDBM50247908; s1971; STL445540; AKOS001589705; AKOS015855406; AKOS025149378; Tox21_110968_1; AB04467; AC-4690; CCG-101045; DB09220; HS-0049; MCULE-6145684901; NC00295; NCGC00025357-02; NCGC00025357-04; 2-(pyridine-3-carbylamino) ethyl nitrate; BN164649; H924; FT-0602677; N0837; SW197675-3; D01810; J10427; T72780; AB00639978-08; AB00639978-09; AB00639978_10; AB00639978_11; A834984; Q862989; SR-01000597534-1; SR-01000597534-5; BRD-K97752965-001-01-6; F0005-2298
• Indication:
  In total 1 Indication(s)
  Angina pectoris [ICD-11: BA40]; Approved; [1]
• Target: ATP-binding cassette transporter C9 (ABCC9); ABCC9_HUMAN; [1]
• Formula: C8H9N3O4
• IsoSMILES: C1=CC(=CN=C1)C(=O)NCCO[N+](=O)[O-]
• InChI: 1S/C8H9N3O4/c12-8(7-2-1-3-9-6-7)10-4-5-15-11(13)14/h1-3,6H,4-5H2,(H,10,12)
• InChIKey: LBHIOVVIQHSOQN-UHFFFAOYSA-N
• PubChem CID: 47528
• ChEBI ID: CHEBI:31905
• TTD Drug ID: D0O2SR
• VARIDT ID: DR01017
• DrugBank ID: DB09220

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-05: Endocrine/nutritional/metabolic diseases

Insulin-resistance syndrome [ICD-11: 5A44]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Tribbles homolog 3 (TRIB3) [1]

• Molecule Alteration: Expression; Down-regulation
• Sensitive Disease: Insulin-resistance syndrome [ICD-11: 5A44.0]
• Experimental Note: Discovered Using In-vivo Testing Model
• Cell Pathway Regulation: PERK signaling pathway; Inhibition; hsa04137
• In Vitro Model: L6 cells; Skeletal muscle; Rattus norvegicus (Rat); CVCL_0385
• In Vivo Model: Adult Sprague-Dawley rats model; Rattus norvegicus
• Experiment for Molecule Alteration: Western blotting analysis
• Experiment for Drug Resistance: Glucose tolerance test, insulin tolerance test
• Mechanism Description: Nicorandil attenuates high glucose-induced insulin resistance by suppressing oxidative stress-mediated ER stress PERK signaling pathway.

References

• Ref 1: Nicorandil attenuates high glucose-induced insulin resistance by suppressing oxidative stress-mediated ER stress PERK signaling pathway .BMJ Open Diabetes Res Care. 2021 Apr;9(1):e001884. doi: 10.1136/bmjdrc-2020-001884. 10.1136/bmjdrc-2020-001884